UNITY Biotechnology, Inc. UNBX
0.06
0.00
0.00%
as of 14 Oct
- Market cap
- $3.4M
- P/E
- 0.0×
Follow UNBX
Growth Flags
show if company had growth for consecutive years
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — | — | 0.00 | 0.00 | — | — |
P/S ratio |
— | 0.00 | — | — | — | 0.00 | 0.00 | — | — |
P/FCF ratio |
— | 0.00 | — | — | — | 0.00 | 0.00 | — | — |
P/Operating CF |
— | (4.82) | — | — | — | (16.21) | (2.39) | — | — |
P/B ratio |
— | 0.00 | — | — | — | 1.37 | 0.50 | — | — |
Price to Tangible BV |
— | 0.00 | — | — | — | 1.37 | 0.50 | — | — |
EV/Sales |
— | 0.00 | — | — | — | 0.00 | 0.00 | — | — |
EV/EBITDA |
— | 1.50 | — | — | — | 0.00 | 0.85 | — | — |
EV/Operating CF |
— | 1.81 | — | — | — | (0.33) | 0.88 | — | — |
EV/FCF |
— | 1.75 | — | — | — | (0.33) | 0.89 | — | — |
Quick Ratio |
24.19 | 11.13 | 10.32 | 7.09 | 6.76 | 5.30 | 4.83 | 5.51 | 2.51 |
Current Ratio |
25.31 | 11.25 | 10.43 | 7.52 | 6.97 | 5.45 | 4.92 | 5.94 | 2.62 |
Net Debt/EBITDA |
4.78 | 1.96 | 2.19 | 1.38 | 0.79 | 1.28 | 1.37 | 1.12 | 0.82 |
Debt/Assets |
0.00% | 0.20% | 0.07% | 0.03% | 18.57% | 17.21% | 16.38% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.35 | 0.36 | 0.36 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.54 | 0.86 | 0.74 | 0.88 | 0.83 | 0.74 | 1.18 | 0.93 | 0.80 |
Capex/Depreciation |
(14.67) | (1.14) | (1.03) | (1.05) | (0.10) | (0.04) | 0.09 | 0.02 | 0.01 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 48.94% | 71.77% | (196.95%) | (58.41%) | (92.19%) | (85.26%) | (76.90%) | (94.36%) | (148.97%) | |
| (30.55%) | (87.54%) | (53.92%) | (49.42%) | (61.03%) | (43.22%) | (35.71%) | (41.95%) | (50.29%) | |
ROIC |
0.00% | (628.56%) | 0.00% | 0.00% | (413.16%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(33.06%) | (50.78%) | (46.98%) | (63.75%) | (94.76%) | (72.44%) | (52.48%) | (90.91%) | (140.77%) |
Average Days of Receivables |
— | 365.00 | — | — | — | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 2,704.27% | 0.00% | 0.00% | 0.00% | 802.53% | 15,618.22% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 695.88% | 0.00% | 0.00% | 0.00% | 481.94% | 8,876.69% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 219.54% | 0.00% | 0.00% | 0.00% | 241.49% | 3,974.15% | 0.00% | 0.00% |
Graham Net Nets |
— | 2.14 | — | — | — | 0.31 | 1.01 | — | — |
Graham Number |
— | 903.62 | — | — | — | 0.00 | 0.00 | — | — |
Earnings Yield |
— | (94.62%) | — | — | — | (74.66%) | (238.51%) | — | — |
Free Cash Flow Yield |
— | (76.67%) | — | — | — | (55.53%) | (185.53%) | — | — |
Revenue per Share |
0.00 | 4.32 | 0.00 | 0.00 | 0.00 | 0.86 | 0.02 | 0.00 | 0.00 |
Operating CF per Share |
(61.58) | (119.94) | (20.03) | (16.60) | (15.40) | (8.07) | (5.52) | (2.51) | (1.24) |
Capex per Share |
(8.43) | (5.28) | (0.45) | (0.36) | (0.13) | (0.03) | 0.03 | 0.01 | 0.00 |
Free Cash Flow per Share |
(70.00) | (125.23) | (20.48) | (16.96) | (15.53) | (8.11) | (5.49) | (2.50) | (1.24) |
Cash per Share |
335.28 | 270.51 | 60.54 | 27.96 | 19.21 | 15.78 | 9.98 | 2.92 | 1.38 |
Shareholders Equity per Share |
0.00 | 284.06 | 56.84 | 27.67 | 16.30 | 10.67 | 5.91 | 1.92 | 0.39 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 284.06 | 56.84 | 27.67 | 16.30 | 10.67 | 5.91 | 1.92 | 0.39 |
Free Cash Flow |
(18.64) | (40.05) | (57.89) | (74.01) | (78.98) | (45.25) | (52.13) | (36.98) | (20.84) |
Working Capital |
89.72 | 80.98 | 156.38 | 112.27 | 86.40 | 73.89 | 76.92 | 38.77 | 15.01 |
Capital Expenditures |
(2.24) | (1.69) | (1.26) | (1.59) | (0.65) | (0.19) | 0.28 | 0.10 | 0.03 |
Net Current Asset Value |
93.41 | 77.70 | 152.28 | 98.97 | 27.43 | 25.36 | 28.27 | 9.31 | (6.90) |
EV/EBIT |
— | 1.45 | — | — | — | 0.00 | 0.80 | — | — |
Capex to Sales |
0.00 | 1.22 | 0.00 | 0.00 | 0.00 | 0.04 | (1.19) | 0.00 | 0.00 |
Net Profit Margin |
0.00% | (3,231.26%) | 0.00% | 0.00% | 0.00% | (1,269.34%) | (18,842.80%) | 0.00% | 0.00% |
Price to Operating Income |
— | 0.00 | — | — | — | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.07 | 0.21 | 0.20 | 0.09 | 0.53 | 0.48 | 0.41 | 1.18 | 0.82 |
Cash ROIC |
(20.88%) | (25.52%) | (18.94%) | (36.69%) | (43.40%) | (32.52%) | (35.18%) | (58.90%) | (81.82%) |
Accounts Receivable Turnover |
— | 0.00 | — | — | — | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Payables |
1.67 | 1.67 | 3.61 | 5.02 | 3.87 | 2.27 | 1.89 | 1.59 | 1.19 |
Average Assets |
99.54 | 51.01 | 141.70 | 166.30 | 153.77 | 140.52 | 124.53 | 95.02 | 51.68 |
Average Common Equity |
(62.12) | (62.22) | 38.79 | 140.70 | 101.79 | 71.22 | 57.83 | 42.24 | 17.45 |
Columns are period end dates